Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

CING

Cingulate Inc

Nov 21 • 01:06PM ET

3.61

+0.15 4.34 %

Healthcare • Biotechnology • USA • NASD

Peers: JNJ ABBV MRK LLY AZN NVS PFE GSK BMY AMGN

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.29	Insider Own	1.92%	Shs Outstand	6.76M	Perf Week	3.44%
Market Cap	24.39M	Forward P/E	-	EPS next Y	-1.69	Insider Trans	0.00%	Shs Float	6.63M	Perf Month	0.84%
Enterprise Value	22.85M	PEG	-	EPS next Q	-0.65	Inst Own	4.30%	Short Float	4.90%	Perf Quarter	-14.15%
Income	-22.06M	P/S	-	EPS this Y	63.43%	Inst Trans	0.09%	Short Ratio	1.80	Perf Half Y	-1.37%
Sales	0.00M	P/B	6.21	EPS next Y	54.69%	ROA	-183.12%	Short Interest	0.32M	Perf YTD	-26.77%
Book/sh	0.58	P/C	3.99	EPS next 5Y	60.26%	ROE	-284.50%	52W High	6.01 -39.93%	Perf Year	-11.95%
Cash/sh	0.91	P/FCF	-	EPS past 3/5Y	71.48% 40.00%	ROIC	-475.88%	52W Low	3.20 12.81%	Perf 3Y	-98.40%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.23% 6.55%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	93.84%	Oper. Margin	-	ATR (14)	0.25	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.26	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	48.76	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.26	EPS Q/Q	26.12%	SMA20	-0.01%	Beta	-0.71	Target Price	30.25
Payout	-	Debt/Eq	1.32	Sales Q/Q	-	SMA50	-4.65%	Rel Volume	0.44	Prev Close	3.46
Employees	13	LT Debt/Eq	0.33	Earnings	Nov 13 BMO	SMA200	-12.03%	Avg Volume	180.82K	Price	3.61
IPO	Dec 08, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-53.41% -	Trades		Volume	47,626	Change	4.34%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-10-25	Initiated	ROTH MKM	Buy	$12
Dec-22-23	Downgrade	Laidlaw	Buy → Hold

Nov-20-25 07:40AM	Cingulate price target lowered to $16 from $17 at Roth Capital (TipRanks)
Nov-18-25 04:27PM	Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25 (Newsfile)
Nov-13-25 08:00AM	Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -12.37%
Nov-10-25 08:00AM	Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301 (GlobeNewswire)
Oct-28-25 08:00AM	Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control (GlobeNewswire)
04:45PM	Loading…
Oct-23-25 04:45PM	Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting (GlobeNewswire) +7.82%
Oct-14-25 08:00AM	FDA Accepts Cingulate's New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date (GlobeNewswire)
Sep-17-25 08:45AM	Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment (GlobeNewswire) -5.85%
Aug-21-25 04:35PM	Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25 (Newsfile) +5.01%
Aug-19-25 08:45AM	Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights (GlobeNewswire) -9.62%
Aug-15-25 09:00AM	Cingulate Provides Management Team Update (GlobeNewswire)
Aug-07-25 05:12AM	Cingulate submits NDA for CTx-1301 for ADHD treatment (Pharmaceutical Business Review) -6.86%
Aug-06-25 08:45AM	Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301 (GlobeNewswire) -16.61%
Jul-29-25 08:00AM	Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301 (GlobeNewswire)
Jul-09-25 08:00AM	Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application (GlobeNewswire)
08:00AM	Loading…
Jun-18-25 08:00AM	Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING) (Newsfile)
May-20-25 08:00AM	Efficacy Results Announced from Cingulate's Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD (GlobeNewswire)
May-14-25 08:00AM	FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301 (GlobeNewswire) +8.70%
May-08-25 04:30PM	Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets (GlobeNewswire)
Apr-29-25 08:00AM	Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD (GlobeNewswire)
Apr-09-25 08:00AM	Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone) (GlobeNewswire)
Apr-03-25 08:00AM	Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301 (GlobeNewswire)
Mar-26-25 05:00PM	Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved (GlobeNewswire) +5.07%
Mar-04-25 09:00AM	Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025 (GlobeNewswire)
Jan-07-25 07:30AM	Final Study Completed for Cingulate's Lead Asset CTx-1301 (GlobeNewswire) -5.43%
Dec-24-24 07:57AM	Cingulate Inc Secures $5M Financing for Strategic Growth (TipRanks)
Dec-23-24 07:30AM	Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000 (GlobeNewswire) +16.10%
Nov-07-24 07:30AM	Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market (GlobeNewswire)
Oct-08-24 03:15PM	Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show (GlobeNewswire) -7.60%
Sep-12-24 08:30AM	Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301 (GlobeNewswire) -8.76%
04:30PM	Loading…
Aug-27-24 04:30PM	Cingulate to Participate in Benzinga All Live Access Event (GlobeNewswire) -19.03%
Aug-23-24 04:45PM	Cingulate Announces Adjournment of Special Meeting (GlobeNewswire) -14.55% +5.99%
Aug-15-24 07:45AM	Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD (GlobeNewswire) +160.16%
Aug-13-24 07:45AM	Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved (GlobeNewswire) -21.06%
Jul-11-24 07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) -25.86%
Jun-28-24 09:15AM	Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds (GlobeNewswire) -45.21%
Jun-25-24 04:30PM	Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event (GlobeNewswire)
09:20AM	Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance (GlobeNewswire)
May-21-24 09:00AM	FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD (GlobeNewswire) +5.08%
May-08-24 01:54PM	CING Stock Earnings: Cingulate Beats EPS for Q1 2024 (InvestorPlace)
07:00AM	Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update (GlobeNewswire)
Apr-30-24 05:45AM	Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access (GlobeNewswire)
Apr-29-24 09:00AM	Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
Apr-16-24 05:00PM	Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024 (GlobeNewswire) +5.16%
Apr-01-24 08:00AM	Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update (GlobeNewswire)
Mar-19-24 04:45PM	Cingulate to Participate in Benzinga All Live Access Event (GlobeNewswire)
Mar-06-24 06:45AM	Cingulate to Attend DCAT Week 2024 in New York City (GlobeNewswire)
Feb-13-24 06:45AM	Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors (GlobeNewswire)
Feb-06-24 04:15PM	Cingulate Announces Closing of $7.5 Million Public Offering (GlobeNewswire) -15.50%
Feb-02-24 09:15AM	Cingulate Announces Pricing of $7.5 Million Public Offering (GlobeNewswire) -60.42%
Jan-29-24 08:00AM	Longtime Cingulate Controller Jennifer Callahan Promoted to CFO (GlobeNewswire) -11.59%
06:45AM	Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market (GlobeNewswire)
Dec-28-23 10:15AM	Why Is Cingulate (CING) Stock Up 160% Today? (InvestorPlace) +146.12%
Dec-06-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 2 on December 7th Register Now (GlobeNewswire) -9.44%
Dec-05-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now (GlobeNewswire)
Dec-01-23 09:00AM	Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone) (GlobeNewswire)
Nov-13-23 04:15PM	Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update (GlobeNewswire)
Oct-31-23 07:00AM	Presenting on the Emerging Growth Conference 64 Day 1 on November 1 Register Now (GlobeNewswire)
Oct-17-23 02:22PM	Cingulate to Host CNS Key Opinion Leader Panel in New York City (GlobeNewswire)
Sep-21-23 01:30PM	Cingulate Inc. to Present at the LD Micro Main Event XVI (GlobeNewswire)
Sep-15-23 07:58AM	Cingulate raises $4M from public offering of almost 7M shares (American City Business Journals) +5.57%
Sep-13-23 04:15PM	Cingulate Announces Closing of $4.0 Million Public Offering (GlobeNewswire) +5.35%
Sep-11-23 09:22AM	Cingulate Announces Pricing of $4.0 Million Public Offering (GlobeNewswire)
06:00AM	Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD (GlobeNewswire)
Sep-08-23 04:31PM	Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium (GlobeNewswire)
Sep-05-23 08:00AM	Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023 (GlobeNewswire)
Aug-14-23 04:15PM	Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update (GlobeNewswire) +12.34%
Jul-27-23 06:25AM	Cingulate Slides As Insider Purchases Lose Another US$45k (Simply Wall St.) -7.51%
Jul-11-23 08:00AM	Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD (GlobeNewswire) -8.11%
Jun-29-23 08:00AM	Cingulate Successfully Manufactures Clinical Supply Initiation of Pediatric Phase 3 Studies to Commence in July and August (GlobeNewswire)
Jun-14-23 03:45PM	Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest (GlobeNewswire)
Jun-08-23 07:00AM	Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD (GlobeNewswire)
May-25-23 03:55PM	Cingulate to Present at 13th Annual LD Micro Invitational (GlobeNewswire) -5.39%
May-12-23 03:45PM	Cingulate, Indegene to Participate in Benzinga All Live Access Event (GlobeNewswire)
May-10-23 04:15PM	Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update (GlobeNewswire)
May-05-23 11:51AM	Breakeven On The Horizon For Cingulate Inc. (NASDAQ:CING) (Simply Wall St.)
May-03-23 06:45AM	Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR Manufacturing Processes to Societal CDMO (GlobeNewswire)
Apr-14-23 02:00PM	Cingulate to Participate in Benzinga All Live Access Event (GlobeNewswire)
Apr-04-23 06:45AM	Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD (GlobeNewswire)
Mar-13-23 06:45AM	Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301 (GlobeNewswire) -28.65%
Mar-10-23 04:05PM	Cingulate Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update (GlobeNewswire) +25.00%
Feb-24-23 10:19AM	Why Cingulate Shares Are Trading Higher Today (Benzinga) +40.54%
07:04AM	Cingulate stock skyrockets after ADHD treatment shows positive trial results (MarketWatch)
Feb-23-23 04:30PM	Cingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset CTx-1301 for ADHD (GlobeNewswire)
Feb-22-23 06:56AM	Daily Vickers Top Insider Picks for 02/22/2023 (Argus Research)
Feb-21-23 07:35AM	Daily Vickers Top Insider Picks for 02/21/2023 (Argus Research)
Feb-17-23 06:27AM	Daily Vickers Top Insider Picks for 02/17/2023 (Argus Research)
Feb-16-23 07:28AM	Daily Vickers Top Insider Picks for 02/16/2023 (Argus Research) -8.61%
Feb-15-23 07:01AM	Daily Vickers Top Insider Picks for 02/15/2023 (Argus Research)
Feb-14-23 06:23AM	Daily Vickers Top Insider Picks for 02/14/2023 (Argus Research)
Feb-13-23 07:30AM	Daily Vickers Top Insider Picks for 02/13/2023 (Argus Research) +25.52%
Jan-09-23 08:25AM	Cingulate begins Phase 3 tests of novel treatment for ADHD (American City Business Journals) -10.80%
Jan-04-23 06:45AM	Cingulate Kickstarts First Phase 3 Trial For ADHD Candidate, Data Expected In First Half 2023 (Benzinga)
06:45AM	Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD (GlobeNewswire)
Dec-01-22 02:00PM	Cingulate Benzinga All Live Access Appearance Rescheduled for December 16 (GlobeNewswire)
Nov-30-22 03:00PM	Cingulate to Participate in Benzinga All Live Access Event (GlobeNewswire) +7.42%
Nov-14-22 06:45AM	Cingulate Inc. Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update (GlobeNewswire)
Nov-03-22 07:00AM	Cingulate Inc. to Present at Investor Summit Group's Q4 Conference (Newsfile)
Nov-01-22 09:02AM	Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD (GlobeNewswire)
Oct-25-22 07:55AM	Cingulate Shares Fall After Timeline Update For Its Lead Candidate In ADHD (Benzinga)

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

CING

Cingulate Inc

Upgrade your FINVIZ experience